Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA7 | P36544 | 4/20 | 0.66 |
| ▸ | CHRNA10 | Q9GZZ6 | 4/20 | 0.66 |
| ▸ | CHRNA9 | Q9UGM1 | 4/20 | 0.66 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | CHKA | P35790 | 8/20 | 0.46 |
| ▸ | ACHE | P22303 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | BCHE | P06276 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5307716 | 0.84 | ALDH1A1 (0.53) | CHRNA7CHRNA10CHRNA9KDM4EALDH1A1 | |
| Hydrochloric Acid SCHEMBL7307884 | 0.82 | ALDH1A1 (0.56) | CHRNA7CHRNA10CHRNA9KDM4EALDH1A1 | |
| SCHEMBL4398944 | 0.79 | CHRNA7 (1.00) | CHRNA7CHRNA10CHRNA9KDM4ERAB9A | |
| SCHEMBL4407306 | 0.77 | CHKA (0.73) | KDM4EALDH1A1RAB9ACHKAACHE | |
| SCHEMBL4404405 | 0.74 | LMNA (0.62) | KDM4EALDH1A1RAB9ACHKALMNA | |
| SCHEMBL10188714 | 0.73 | CHRNA7 (0.73) | CHRNA7CHRNA10CHRNA9CHKA | |
| SCHEMBL5295848 | 0.72 | CHRNA7 (0.50) | CHRNA7CHRNA10CHRNA9KDM4ERAB9A | |
| SCHEMBL13334263 | 0.71 | CHRNA7 (0.80) | CHRNA7CHRNA10CHRNA9ACHEBCHE | |
| SCHEMBL19601103 | 0.71 | KDM4A (0.43) | CHRNA7CHRNA10CHRNA9KDM4EALDH1A1 | |
| Bromide SCHEMBL3310517 | 0.70 | CHRNA7 (0.81) | CHRNA7CHRNA10CHRNA9ACHEBCHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8178678-B2 | Bis-quaternary ammonium salts and methods for modulating neuronal nicotinic acetylcholine receptors | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (US) | 2012-05-15 | — | — | US | disclosed |
| US-20100069432-A1 | Bis-Quaternary Ammonium Salts and Methods for Modulating Neuronal Nicotinic Acetylcholine Receptors | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (US) | 2010-03-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100069432-A1 | Bis-Quaternary Ammonium Salts and Methods for Modulating Neuronal Nicotinic Acetylcholine Receptors | CHRNA2, CHRNA5, CHRNA4 | CHRNA7 7/4885CHRNA10 4/4885CHRNA9 12/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.